JPH0352884A - Fo-608a substance and production thereof - Google Patents
Fo-608a substance and production thereofInfo
- Publication number
- JPH0352884A JPH0352884A JP18826189A JP18826189A JPH0352884A JP H0352884 A JPH0352884 A JP H0352884A JP 18826189 A JP18826189 A JP 18826189A JP 18826189 A JP18826189 A JP 18826189A JP H0352884 A JPH0352884 A JP H0352884A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- culture
- cholesterol
- penicillium
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 241000228168 Penicillium sp. Species 0.000 claims abstract description 4
- NUYFKDBCHFKOBT-IBGZPJMESA-N AS-186b Chemical compound O1C2=C(O)C=C(C)C=C2COC(=O)C2=C1C=CC([C@H](CC(C)C)OC(C)=O)=C2OC NUYFKDBCHFKOBT-IBGZPJMESA-N 0.000 claims description 23
- 241000228143 Penicillium Species 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 238000001819 mass spectrum Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RNIZTMIJCBCDBR-XJSVZPCESA-N neokadsuranin Chemical compound C1([C@@H]2O[C@H]3[C@H]([C@H]2C)C)=CC=2OCOC=2C(OC)=C1C1=C3C=C(OC)C(OC)=C1OC RNIZTMIJCBCDBR-XJSVZPCESA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 8
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000005516 coenzyme A Substances 0.000 description 7
- 229940093530 coenzyme a Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- -1 acyl coenzyme A Chemical compound 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- OCKPCBLVNKHBMX-UHFFFAOYSA-N n-butyl-benzene Natural products CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はFO−6 0 8A物質およびその製造法に閲
する.更に詳しくは、アシルコエンザイムAコレステロ
ールアシル転位酵素阻害作用を有する新規物質、FO−
608A物質およびその製造法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention pertains to the FO-608A substance and its manufacturing method. More specifically, FO-, a new substance with acyl coenzyme A cholesterol acyl transferase inhibitory
608A substance and its manufacturing method.
従来、いくつかの抗高脂血症薬物が知られていたが、未
だに有効な物質は得られていない。Although several antihyperlipidemic drugs have been known in the past, no effective substance has yet been obtained.
近年、食生活の向上に伴い戒大の高脂血症や動脈硬化な
どコレステロール蓄積に起因する症状が現代病として問
題視されている.コレステロールはアシルコエンザイム
Aのアシル基転位によりコレステロールエステルとなり
、細胞内および血中リボ蛋白に蓄積される.このアシル
基転位反応を触媒する酵素がアシルコAコレステロール
アシル転位酵素であり、コレステロールの腸管からの吸
収および冠動脈における泡末細胞の形或に深く係わって
いる.したがって、アシルコエンザイムAコレステロー
ルアシル転位酵素を阻害する物質は、かかる疾病に有効
であることが推察される.
かかる実情において、アシルコエンザイムAコレステロ
ールアシル転位酵素阻害活性を有する物質を提供するこ
とは、高脂血症やそれに基く動脈硬化などの戒人病の治
療上有用なことである。In recent years, as dietary habits have improved, symptoms caused by cholesterol accumulation, such as hyperlipidemia and arteriosclerosis, have become a problem as modern diseases. Cholesterol becomes cholesterol ester through acyl group rearrangement of acyl coenzyme A, and is accumulated in cells and in blood riboproteins. The enzyme that catalyzes this acyl group transfer reaction is acylco-A cholesterol acyltransferase, which is deeply involved in the absorption of cholesterol from the intestinal tract and the formation of foam terminal cells in coronary arteries. Therefore, it is presumed that substances that inhibit acyl-coenzyme A cholesterol acyltransferase are effective against such diseases. Under these circumstances, providing a substance having acyl-coenzyme A cholesterol acyltransferase inhibitory activity is useful in the treatment of hyperlipidemia and Kaito's diseases such as arteriosclerosis based thereon.
本発明者らは、微生物の生産する代謝産物について研究
を続けた結果、新たに土壌から分離したFO−608菌
株の培養中にアシルコエンザイムAコレステロールアシ
ル転位酵素阻害活性を有する物質が産生されることを見
出した。次いで、該培養物から該アジルコエンザイムA
コレステa−ルアシル転位酵素阻害活性を分離、精製し
た結果、このような化学構造を有する物質は従来全く知
られていないことから、本物質をFO−608Aと称す
ることにした.本発明は、かかる知見に基いて完或され
たものであって、式
で表される新規物質、FO−6 0 8A物質に関する
ものである。更に、本発明はペニシリウム属に属し、F
O−608A物質を生産する能力を有する微生物を培地
に培養し、培養物にFO−608Aを蓄積せしめ、該培
養物からFO−6 0 8A物質を採取することを特徴
とする新規物1iFo−608A物質あるいはそれらの
塩の製造法を提供するものである.FO−608A物質
を生産する能力を有する微生物(以下、FO−6 0
8A物質生産菌と称する〉は、ペニシリウム属に属する
が、例えば本発明者らが分離したべニシリウム属に属す
るFO−608菌株は、本発明に最も有効に使用される
菌株の一例であって、本菌株の菌学的性質を示すと次の
通りでる.本発明のFO−608A9J質を生産するた
めに使用される菌株としては、例えば本発明者らによっ
て、土壌から新たに分離されたべニシリウム エスピ(
Penicillium sp.)FO−608株が
挙げられる.
本菌株の菌学的性状を示すと次のとうりである。As a result of continuing research on metabolites produced by microorganisms, the present inventors discovered that a substance with acyl-coenzyme A cholesterol acyltransferase inhibitory activity was produced during cultivation of the FO-608 strain newly isolated from soil. I found out. Then, the azircoenzyme A is extracted from the culture.
As a result of separating and purifying the cholesteryl acyltransferase inhibitory activity, we decided to name this substance FO-608A because no substance with such a chemical structure was previously known. The present invention was completed based on this knowledge, and relates to a new substance, FO-608A substance, represented by the formula. Furthermore, the present invention belongs to the genus Penicillium, F.
A novel product 1iFo-608A characterized in that a microorganism capable of producing an O-608A substance is cultured in a medium, FO-608A is accumulated in the culture, and the FO-608A substance is collected from the culture. It provides methods for producing substances or their salts. Microorganisms capable of producing FO-608A substances (hereinafter referred to as FO-60
8A substance producing bacteria> belongs to the genus Penicillium, and for example, the FO-608 strain belonging to the genus Benicillium isolated by the present inventors is an example of a strain most effectively used in the present invention, The mycological properties of this strain are as follows. The bacterial strain used to produce the FO-608A9J material of the present invention includes, for example, Benicillium sp., which was newly isolated from soil by the present inventors.
Penicillium sp. ) FO-608 strain is mentioned. The mycological properties of this strain are as follows.
■.形態的性質
本菌株は、麦芽汁寒天培地、バレイショ・ブドウ糖寒天
培地、ツアベック寒天培地、オートξ−ル寒天培地およ
びYpSs寒天培地などで比較的良好に生育し、分生子
の着生は良好である.ツアベック寒天培地に生育したコ
ロニーを顕微鏡で観察すると、菌糸は透明で隔壁を有し
ており、分生子柄は基底菌糸より直生し、その表面は滑
面である.ペニシラスはメトレとフィアライドから構威
される複輪生体一対称型である。メトレの大きさは9〜
11×2〜2.5μで3〜6個着生する。フィアライド
はペン先型で3〜6個群生し、大きさは10〜14X0
.9〜1.7μである.
はじめはフィアロ型分生子がフィアライドの頂端に1個
着生し、培養時間の経過とともに連鎖状となり、最終的
にはこの連鎖は150μm前後に達する.電子顕微鏡で
観察すると、分生子はだ円形で、大きさは2.5〜3X
1.8〜2.2μであり、その表面は滑面である。■. Morphological Properties This strain grows relatively well on wort agar, potato-dextrose agar, Zurbaek agar, oat ξ-le agar, YpSs agar, etc., and has good conidial settlement. .. When a colony grown on a Zuavec agar medium is observed under a microscope, the hyphae are transparent and have septa, the conidiophores grow straight from the basal hyphae, and their surfaces are smooth. Penicillas is a two-wheeled, symmetrical creature composed of Metre and Phialide. The size of the metre is 9~
11 x 2-2.5μ and 3-6 pieces grow. Phialides are pen-shaped and grow in clusters of 3 to 6 pieces, and the size is 10 to 14X0.
.. It is 9 to 1.7μ. At first, a single phialoid conidium attaches to the apex of the phialide, and as the culture time progresses, it forms a chain, and eventually this chain reaches around 150 μm. When observed with an electron microscope, the conidia are oval in shape and have a size of 2.5 to 3X.
It has a diameter of 1.8 to 2.2μ, and its surface is smooth.
■.培養上の諸性状
<11各種培地上で25℃、12日間培養した場合の肉
眼的観察結果を第1表に示す。■. Various culture properties <11 Table 1 shows the results of macroscopic observation when cultured on various media at 25° C. for 12 days.
(2)上記培地における37℃、12日間培養した場合
の生育状態は、抑制的(コロニー直径、20〜30mm
)で、菌糸は拡散せず、ビロード状であった.又、5℃
、12日間培養した場合の生育状態は、きわめて抑制的
(10mm以下)で、分生子は形或しなかった.
前記のすべての培地には、菌の生育に伴う分泌液および
菌核の形或は観察されなかった.■.生理的、生態的性
状
(1)最適生育条件
本菌株の最適生育条件は、麦芽汁寒天培地においてpH
4〜7、温度18〜33℃である。(2) When cultured in the above medium at 37°C for 12 days, the growth state was suppressive (colony diameter, 20-30 mm).
), the hyphae did not spread and were velvety. Also, 5℃
The growth condition when cultured for 12 days was extremely suppressive (less than 10 mm), and no conidia were formed. In all of the above-mentioned media, no secretions or sclerotia accompanying growth of the fungus were observed. ■. Physiological and ecological properties (1) Optimal growth conditions The optimal growth conditions for this strain are wort agar medium with pH
4-7, temperature 18-33°C.
(2)生育の範囲
本菌株の生育範囲は麦芽汁寒天培地においてpH2〜9
、温度15〜39℃である.
(3)好気性、嫌気性の区別
好気性
以上の諸性状中、形態観察の結果から本菌株がペニシリ
ウム属に属することが明らかとなった。なお、本菌株は
ペニシリウム エスピー.FO−608(Penici
11 1um sp. FO−608)と
して工業技術院微生物工業技術研究所に寄託されている
.(FERM P−10776).以上、FO−60
8A物質生産菌について説明したが、菌の一般的性状と
して菌学上の性状はきわめて変異し易く、一定したもの
ではなく、自然的にあるいは通常行われる紫外線照射ま
たは変異誘導体、例えばN−メチルーN−二トローN−
二トロソグアニジン、エチルメタンスルホネートなどを
用いる人工的変異手段により変異することは周知の事実
であり、このような人工的変異株は勿論、自然変異株も
含め、ペニシリウム属に属し、FO−608A物質を生
産する能力を有する菌株はすべて本発明に使用すること
ができる.また、細胞融合、遺伝子操作などの細胞工学
的に変異させた菌株もFO−6 0 8A物質生産菌と
して包含される.
本発明においては、先ずペニシリウムに属する物質FO
−6 0 8A生産菌が培地に培養される。本閑の培養
においては、通常真菌の培養法が一般に用いられる.培
地としては、微生物が同化し得る炭素源、責化し得る窒
素源、さらには必要に応じて無機塩などを含有させた栄
養培地が使用される。同化し得る炭素源としては、ブド
ウ糖、シ!I糖、糖蜜、デキストリン、セルロースなど
が単独または組み合わせて用いられる。消化し得る窒素
源としては、ベブトン、肉エキス、酵母エキス、乾燥酵
母、大豆粉、コーン・ステーブ・リカー、綿実粕、カゼ
イン、大豆蛋白加水分解物、アミノ酸、尿素などの有機
窒素源、硝酸塩、アンモニウム塩などの無機窒素化合物
が単独または組み合わせて用いられる.その他必要に応
じてナトリウム塩、カリウム塩、カルシウム塩、マグネ
シウム塩、リン酸塩などの無機塩、重金属塩類が添加さ
れる。さらに、培地には、必要に応じて、本菌の生育や
FO−608A物質の生産を促進する微量栄養素、発育
促進物質、前駆物質などを適当に添加してもよい.
培養は通常振とうまたは通気攪拌培養などの好気的条件
下で行うのがよい.工業的には深部通気攪拌培養が好ま
しい。培養のpHは中性付近で培養を行うのが好ましい
。培養温度は20〜37℃で行い得るが、通常は24〜
30℃に保つのがよい。培養時間は、液体の場合、通常
3〜6日培養を行うと、本物質FO−608A物質が生
或蓄積されるので、培養中の蓄積量が最大に達した時に
、培養を終了すればよい.これらの培地組或、培地の液
性、培養温度、培養速度、通気量などの培養条件は使用
する菌株の種類や外部の条件などに応じて好ましい結果
が得られるように適宜調節、選択されることはいうまで
もない。液体培養において、発泡があるときは、シリコ
ン油、植物油、界面活性剤などの消泡剤を適宜使用でき
る。(2) Growth range The growth range of this strain is pH 2 to 9 on wort agar medium.
, the temperature is 15-39°C. (3) Distinction between aerobic and anaerobic Among the various properties beyond aerobic, morphological observation revealed that this strain belongs to the genus Penicillium. This strain is Penicillium sp. FO-608 (Penici
11 1um sp. It has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology as FO-608). (FERM P-10776). That’s all, FO-60
Although we have explained the 8A substance-producing bacteria, the general properties of bacteria are that their mycological properties are extremely variable and not constant, and that they are susceptible to natural or commonly used ultraviolet irradiation or mutated derivatives, such as N-methyl-N. -Nitoro N-
It is a well-known fact that mutations occur through artificial mutation methods using nitrosoguanidine, ethyl methanesulfonate, etc., and not only such artificial mutant strains but also natural mutant strains belong to the genus Penicillium and the FO-608A substance Any strain that has the ability to produce can be used in the present invention. In addition, strains mutated by cell engineering such as cell fusion or genetic manipulation are also included as FO-608A substance-producing bacteria. In the present invention, first, a substance belonging to Penicillium FO
-608A producing bacteria are cultured in a medium. In culturing Honkan, a fungal culture method is generally used. As the medium, a nutrient medium containing a carbon source that can be assimilated by microorganisms, a nitrogen source that can be oxidized, and, if necessary, an inorganic salt is used. Assimilable carbon sources include glucose, shi! I-sugar, molasses, dextrin, cellulose, etc. may be used alone or in combination. Digestible nitrogen sources include Bebutone, meat extract, yeast extract, dried yeast, soy flour, corn stave liquor, cottonseed meal, casein, soy protein hydrolyzate, amino acids, organic nitrogen sources such as urea, and nitrates. , inorganic nitrogen compounds such as ammonium salts are used alone or in combination. Other inorganic salts and heavy metal salts such as sodium salts, potassium salts, calcium salts, magnesium salts, and phosphates may be added as necessary. Furthermore, micronutrients, growth-promoting substances, precursor substances, etc. that promote the growth of this bacterium and the production of the FO-608A substance may be added to the medium as necessary. Cultivation is usually carried out under aerobic conditions such as shaking or aerated culture. Industrially, deep aeration agitation culture is preferred. It is preferable to culture at a pH around neutrality. The culture temperature can be 20-37°C, but usually 24-37°C.
It is best to keep it at 30°C. Regarding the culture time, in the case of a liquid, the FO-608A substance is usually produced or accumulated after 3 to 6 days of culture, so the culture should be terminated when the amount accumulated during culture reaches the maximum. .. These culture conditions such as culture medium composition, medium liquid properties, culture temperature, culture speed, aeration amount, etc. are adjusted and selected as appropriate to obtain favorable results depending on the type of bacterial strain used and external conditions. Needless to say. When foaming occurs in liquid culture, antifoaming agents such as silicone oil, vegetable oil, and surfactants can be used as appropriate.
このようにして得られた培養物に蓄積されるFO−6
0 8A物質は菌体内および培養濾液中に含有されるの
で、培養物を遠心分離して培養濾液と菌体とに分離し、
各々から本物質FO−6 0 8A物質を採取するのが
有利である。FO-6 accumulated in the cultures thus obtained
Since the 08A substance is contained in the bacterial cells and the culture filtrate, the culture is centrifuged to separate the culture filtrate and the bacterial cells,
Advantageously, the present material FO-6 0 8A material is taken from each.
培養濾液からF○−608A物質を採取するには、先ず
培養濾液を酢酸エチル、酢酸ブチル、ベンゼンなどの非
親水性有機溶媒で抽出し、抽出液を減圧濃縮して粗製の
物質、FO−608A物質が得られる。該粗製物質はさ
らに脂溶性物質の精製に通常用いられる公知の方法、例
えばシリカゲル、アルξナなどの担体を用いるカラムク
ロマトグラフイーによりFO−6 0 8A物質を分離
精製することができる.菌体からFO−608A物質を
採取するには、菌体を含水アセトン、含水メタノールな
どの含水親水性有機溶媒で抽出し、得られた抽出液を減
圧濃縮し、その濃縮物を酢酸エチル、酢酸ブチル、ベン
ゼンなどの非親水性有機溶媒で抽出し、得られた抽出液
は、前記の培養濾液から得た抽出液と合わせて分離精製
するか、あるいは前記と同じ方法によりFO−608A
物質を分離精製するこができる.次に、本発明のFO−
6 0 8A物質の理化学的性状について述べる.
〔l)FO−608A物質
(1)分子式:Cz+HgiOr (高分解能スペク
トルでm/z414が観察さ
れた)
(2)分子量:414 (マススペクトルよりm/z4
14(M”)が観察された)
(3)比旋光度: (α)D−57.6 (C=1、
クロロホルム、)
(4)紫外線吸収スペクトル(エタノール中):第1図
の通り
(5)赤外線吸収スペクトル(四塩化炭素中):第2図
の通り
(6)溶媒に対する溶解性
:メタノール、エタノール、アセトニ
トリル、酢酸エチル、ベンゼンに可
溶、水に不溶
(7)塩基性、酸性、中性の区別
:徽酸性
(8)物質の色、形状
:白色粉末
(9)プロトン核磁気共鳴スペクトル(重クロロホルム
中)
:第3図の通り
aφ化学構造:
次に、本発明のF○−608A物質の生物学的性状およ
び毒性について述べる.
?シルコエンザイムAコレステロールアシル転位酵素活
性に対する影響はラット肝ミクロソーム画分より調整し
た粗酵素を用い300μM (1 −”C)0 1 e
o y 1−COA : 3mg/mj!コレステロ
ールを各々20μl (0.02μCl)i6.67μ
t添加し、反応させ、コレステロール画分をクロロホル
ムで抽出後、TLC (キーゼルゲルGF■4、展開溶
媒として石油エーテル:ジエチルエーテル:酢酸、90
:10;1)でコレステロール画分を分離し、液体シン
チレーシッンカウンターでアシルコエンザイムAコレス
テロールアシル転位酵素活性ヲ測定した。本酵素に対す
る50%阻害する濃度を算定した結果は50μg /
m lであった.(2)毒性
FO−608A物質を1 0 0 m g / k g
をマウス腹腔内に投与したが、何ら毒性変化は認められ
なかった.
以上のように、本発明のFO−6 0 8A物質は毒性
が低く、アシルコエンザイムAコレステロールアシル転
位酵素に対して著しい阻害活性を示すことから、ヒトの
コレステロール蓄積に起因する疾病の予防および治療に
有用であると考えられる。To collect the F○-608A substance from the culture filtrate, first extract the culture filtrate with a non-hydrophilic organic solvent such as ethyl acetate, butyl acetate, or benzene, and concentrate the extract under reduced pressure to obtain the crude substance, FO-608A. Substances are obtained. The crude substance can be further purified to separate and purify the FO-608A substance by a known method commonly used for purifying fat-soluble substances, such as column chromatography using a carrier such as silica gel or alumina. To collect the FO-608A substance from bacterial cells, the bacterial cells are extracted with a hydrophilic organic solvent containing water such as aqueous acetone or methanol, and the resulting extract is concentrated under reduced pressure. Extraction is performed with a non-hydrophilic organic solvent such as butyl or benzene, and the resulting extract is separated and purified by combining it with the extract obtained from the culture filtrate, or by the same method as above.
Substances can be separated and purified. Next, the FO-
6 Describe the physical and chemical properties of the 8A substance. [l) FO-608A substance (1) Molecular formula: Cz+HgiOr (m/z 414 was observed in the high-resolution spectrum) (2) Molecular weight: 414 (m/z 4 from the mass spectrum
(3) Specific optical rotation: (α)D-57.6 (C=1,
(4) Ultraviolet absorption spectrum (in ethanol): As shown in Figure 1 (5) Infrared absorption spectrum (in carbon tetrachloride): As shown in Figure 2 (6) Solubility in solvents: methanol, ethanol, acetonitrile , ethyl acetate, soluble in benzene, insoluble in water (7) Basic, acidic, neutral: acidic (8) Color and shape of substance: white powder (9) Proton nuclear magnetic resonance spectrum (in deuterochloroform) ): aφ chemical structure as shown in Figure 3: Next, the biological properties and toxicity of the F○-608A substance of the present invention will be described. ? The effect on silcoenzyme A cholesterol acyltransferase activity was determined using crude enzyme prepared from rat liver microsomal fraction at 300 μM (1-”C)0 1 e.
o y 1-COA: 3 mg/mj! 20μl each (0.02μCl) of cholesterol i6.67μ
After extracting the cholesterol fraction with chloroform, TLC (Kieselgel GF 4, petroleum ether: diethyl ether: acetic acid as a developing solvent, 90%
The cholesterol fraction was separated using 10:1) and the activity of acyl coenzyme A cholesterol acyltransferase was measured using a liquid scintillation counter. The concentration that inhibits this enzyme by 50% was calculated and the result was 50μg/
It was ml. (2) 100 mg/kg of toxic FO-608A substance
was administered intraperitoneally to mice, but no toxic changes were observed. As described above, the FO-608A substance of the present invention has low toxicity and exhibits significant inhibitory activity against acyl-coenzyme A cholesterol acyltransferase, so it is useful for the prevention and treatment of diseases caused by cholesterol accumulation in humans. It is considered useful.
次に、実施例を挙げて本発明を具体的に説明する。Next, the present invention will be specifically explained with reference to Examples.
5 0 0 m l容三角フラスコにグルコース0.1
%、スターチ2.4%、ペブトン0.3%、肉エキス0
.3%、イーストエキストラクト0.5%、炭酸カルシ
ウム0.4%を含む培地(pH7.0に調製)100m
Itを仕込み、綿栓後、蒸気滅菌し、寒天培地上に生育
させたべニシリウム エスビー. FO−608 (F
ERM P−10776)を白金耳にて無菌的に接種
し、27℃で48時間振とう培養して種培養液を得た。0.1 glucose in a 500 ml Erlenmeyer flask
%, starch 2.4%, pebtone 0.3%, meat extract 0
.. 100 m of medium containing 3% yeast extract, 0.5% yeast extract, and 0.4% calcium carbonate (adjusted to pH 7.0)
Benicillium S.B. was prepared with It, plugged with cotton, steam sterilized, and grown on an agar medium. FO-608 (F
ERM P-10776) was aseptically inoculated using a platinum loop, and cultured with shaking at 27°C for 48 hours to obtain a seed culture.
一方、30lジャーファーメンタ−1基にグルコース1
. 0%、グリセロール3%、ペブトン0.5%、塩
化ナトリウム0.2%、寒天0.1%(p87.0に調
整)に仕込み、蒸気滅菌冷却後、種培養した種培養液2
0 0mlを無菌的に移植し、攪拌速度250rpm
、通気量10l/分の培養条件下で27℃で160時間
通気攪拌培養した.培養後、培養液を遠心分離して上清
201と菌体に分離し、菌体は80%アセトン水1.5
1で抽出し、抽出液を約ll迄減圧濃縮後、その濃縮液
を上澄に加えた。これを酢酸エチル18lで抽出し、抽
出液を減圧:a縮して粗製物10.3gを得た.この粗
製物を酢酸エチル3 0mj+に懸濁し、シリカゲル(
2 5 0 g1メルク社製、Art.9385)のカ
ラムにチャージし、クロロホルムで溶出するカラムクロ
マトグラフィーを行った。各フラクションは50mJづ
つ分画し、活性或分を含むフラクションを集め、減圧乾
固して粗活性物質1.5gを得た.これを5回に分けて
高速液体クロマトグラフィーにより分離精製した。装置
はトリロータV(日本分光社製〉を用い、カラムはYM
C−Pack A−343 (ODS系樹脂、山村化
学研究所製〉を用い、溶媒系は、65%のアセトニトリ
ル水を用い、検出はUV280nm、流速は8mlll
分で行った.その結果FO−608A物質6 0mgを
単離した.On the other hand, 1 glucose per 30 liter jar fermentor
.. 0%, glycerol 3%, pebtone 0.5%, sodium chloride 0.2%, agar 0.1% (adjusted to p87.0), steam sterilized, cooled, and seed cultured Seed culture solution 2
Transfer 0 0 ml aseptically and stir at 250 rpm.
The cells were cultured with aeration and agitation for 160 hours at 27°C under culture conditions with an aeration rate of 10 l/min. After culturing, the culture solution is centrifuged to separate supernatant 201 and bacterial cells, and the bacterial cells are mixed with 80% acetone water 1.5
1, the extract was concentrated under reduced pressure to about 1 liter, and the concentrated solution was added to the supernatant. This was extracted with 18 liters of ethyl acetate, and the extract was condensed under reduced pressure to obtain 10.3 g of a crude product. This crude product was suspended in 30 mj+ of ethyl acetate, and silica gel (
250 g1 Merck & Co., Art. Column chromatography was performed by charging a column of 9385) and eluting with chloroform. Each fraction was divided into 50 mJ fractions, and fractions containing active fractions were collected and dried under reduced pressure to obtain 1.5 g of crude active substance. This was separated and purified by high performance liquid chromatography in 5 parts. The device used was Trirotor V (manufactured by JASCO Corporation), and the column was YM.
C-Pack A-343 (ODS resin, manufactured by Yamamura Chemical Research Institute) was used, the solvent system was 65% acetonitrile water, detection was at UV 280 nm, and the flow rate was 8 ml.
I went there in minutes. As a result, 60 mg of FO-608A substance was isolated.
第1図はFO−6 0 8A物質の紫外線吸収スペクト
ル、第2図は該物質の赤外線吸収スペクトル、第3図は
該物質のプロトン核磁気共鳴スペクトルを示す.Figure 1 shows the ultraviolet absorption spectrum of the FO-608A substance, Figure 2 shows the infrared absorption spectrum of the substance, and Figure 3 shows the proton nuclear magnetic resonance spectrum of the substance.
Claims (3)
生産する能力を有する微生物を培地に培養し、培養中に
FO−608A物質を蓄積せしめ、該培養物からFO−
608A物質を採取することを特徴とするFO−608
A物質あるいはそれらの塩の製造法。(2) A microorganism belonging to the genus Penicillium and having the ability to produce FO-608A substance is cultured in a medium, FO-608A substance is accumulated during the culture, and FO-608A substance is accumulated from the culture.
FO-608 characterized by collecting 608A substance
A method for producing substances or their salts.
生産する能力を有する微生物がペニシリウムエスピー.
FO−608(Penicililumsp.FO−6
08FERMP−10776である特許請求の範囲第2
項記載の製造法。(3) A microorganism that belongs to the genus Penicillium and has the ability to produce the FO-608A substance is Penicillium sp.
FO-608 (Penicililum sp. FO-6
08FERMP-10776
Manufacturing method described in section.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18826189A JP2710834B2 (en) | 1989-07-20 | 1989-07-20 | FO-608A substance and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18826189A JP2710834B2 (en) | 1989-07-20 | 1989-07-20 | FO-608A substance and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0352884A true JPH0352884A (en) | 1991-03-07 |
JP2710834B2 JP2710834B2 (en) | 1998-02-10 |
Family
ID=16220581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP18826189A Expired - Lifetime JP2710834B2 (en) | 1989-07-20 | 1989-07-20 | FO-608A substance and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2710834B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012175A1 (en) * | 1992-11-25 | 1994-06-09 | Taisho Pharmaceutical Co., Ltd. | Lipid level depressant containing penicillide compound as active ingredient |
WO1994018190A1 (en) * | 1993-02-08 | 1994-08-18 | Taisho Pharmaceutical Co., Ltd. | Depsidone compound |
WO2004039364A1 (en) * | 2002-10-31 | 2004-05-13 | Bayer Healthcare Ag | Novel use of dioxocin-5-on derivatives |
WO2004039453A3 (en) * | 2002-10-31 | 2004-08-05 | Bayer Healthcare Ag | 7h-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof |
-
1989
- 1989-07-20 JP JP18826189A patent/JP2710834B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012175A1 (en) * | 1992-11-25 | 1994-06-09 | Taisho Pharmaceutical Co., Ltd. | Lipid level depressant containing penicillide compound as active ingredient |
WO1994018190A1 (en) * | 1993-02-08 | 1994-08-18 | Taisho Pharmaceutical Co., Ltd. | Depsidone compound |
WO2004039364A1 (en) * | 2002-10-31 | 2004-05-13 | Bayer Healthcare Ag | Novel use of dioxocin-5-on derivatives |
WO2004039453A3 (en) * | 2002-10-31 | 2004-08-05 | Bayer Healthcare Ag | 7h-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof |
JP2006508938A (en) * | 2002-10-31 | 2006-03-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 7H-Dibenzo [b, g] [1,5] dioxocin-5-one derivatives and their use |
Also Published As
Publication number | Publication date |
---|---|
JP2710834B2 (en) | 1998-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3233476B2 (en) | FO-1289 substance and method for producing the same | |
JP2993767B2 (en) | FO-1289A substance and method for producing the same | |
JPH10287662A (en) | Fo-5637a and b substance, and their production | |
JPH08239385A (en) | Fo-1289 substance and its production | |
US4943528A (en) | Process for the production of optically active (R)-(-)-3-halo-1,2-propanediol | |
JPH0352884A (en) | Fo-608a substance and production thereof | |
JPH02283295A (en) | Production of optically active (r)-(-)-3-halo-1,2-propanediol | |
JP4160149B2 (en) | Novel FO-6969 substance and process for producing the same | |
JP2872311B2 (en) | FO-608B, C substance and method for producing the same | |
JP3074038B2 (en) | FO-1513A substance and method for producing the same | |
JP3434860B2 (en) | FO-2546 substance and method for producing the same | |
JP2002275194A (en) | New fo-6979-m0 substance, fo-6979-m1 substance, fo-6979-m2 substance, fo-6979-m3 substance and fo-6979-m4 substance and method for producing the same | |
JPH07242636A (en) | Fo-3216 substance and its production | |
JP3580875B2 (en) | FO-4259 substance and method for producing the same | |
JPH03227971A (en) | Carbazole compound | |
WO1999024439A1 (en) | Novel substance ft-0554 and process for producing the same | |
JP3862277B2 (en) | Novel bile acid converting microorganism | |
JPH0856688A (en) | Substance fo-2546 and its production | |
JPH04248989A (en) | Production of 8-hydroxycarbostyril and/or 8-hydroxycoumarin | |
JPH01199582A (en) | Novel antibiotic fo-125a4, a5 or b and production thereof | |
JPS62228074A (en) | Substance ss50408 and production thereof | |
JPS6135788A (en) | Physiologically active substance ss20846a and its preparation | |
JPS62149693A (en) | Antibiotic substance ss42227b and production thereof | |
JPS5945894A (en) | Preparation of coenzyme q10 | |
JPH07206886A (en) | Farnesyltransferase inhibitor fo-3929 and its production |